Indian Firm Panacea Partners With US Company to Make COVID Vaccine

Indian Firm Panacea Partners With US Company to Make COVID Vaccine

Published10 Jun 2020, 10:38 AM IST
Fit
1 min read

Indian firm Panacea Biotec Ltd. and US-based Refana Inc. will be joining hands to produce and distribute a potential vaccine for COVID-19, according to a Livemint report.

Panacea Biotec will be liable for product development and commercial manufacturing of an inactivated virus-based vaccine, the Indian firm announced in an exchange filing.

The collaborative aim is to create more than 500 million doses of the vaccine, along with 40 million doses awaited to be available by next year, Livemint quoted Jain.

Clinical development would be undertaken by the joint venture and regulatory submissions will be made globally. Panacea Biotec and Refana will undertake sales and distribution of the vaccine after the regulatory approval in their own territories.

As of now, about 130 vaccines are under development stages, out of which 10 are under clinical trials.

(The Quint is now available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!